Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL845155 | 0.84 | HRH3 (0.52) | KDM4EALDH1A1L3MBTL1SIGMAR1 | |
| SCHEMBL23113743 | 0.84 | HRH3 (0.47) | KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL27729397 | 0.82 | HRH3 (0.50) | KDM4EALDH1A1L3MBTL1SIGMAR1 | |
| SCHEMBL161004 | 0.82 | HRH3 (0.55) | KDM4EALDH1A1POLBSIGMAR1 | |
| SCHEMBL27729240 | 0.81 | HRH3 (0.53) | KDM4EALDH1A1POLBSIGMAR1 | |
| SCHEMBL2476102 | 0.79 | SIGMAR1 (0.62) | MEN1KMT2AALDH1A1SIGMAR1 | |
| SCHEMBL27826705 | 0.79 | ALDH1A1 (0.51) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL62595 | 0.79 | HRH3 (0.53) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL61472 | 0.79 | MC4R (0.62) | KDM4EALDH1A1POLBSIGMAR1 | |
| SCHEMBL2971636 | 0.78 | KDM4E (0.61) | MEN1KMT2AKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1851219-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | Miikana Therapeutics, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060199829-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006088949-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199829-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | MEN1 3925/4885KMT2A 82/4885KDM4E 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.